|
CN101511840A
(zh)
*
|
2006-04-26 |
2009-08-19 |
吉宁特有限公司 |
磷酸肌醇3-激酶抑制剂化合物及其使用方法
|
|
PT2300013T
(pt)
|
2008-05-21 |
2017-10-31 |
Ariad Pharma Inc |
Derivados de fósforo como inibidores de cinases
|
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
|
NZ620174A
(en)
|
2009-09-16 |
2016-08-26 |
Celgene Avilomics Res Inc |
Protein kinase conjugates and inhibitors
|
|
WO2011060321A1
(en)
|
2009-11-16 |
2011-05-19 |
Chdi, Inc. |
Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
|
|
EP2519664A4
(en)
|
2009-12-30 |
2014-03-12 |
Avila Therapeutics Inc |
LIGAND-RELATED COVALENTS MODIFYING A PROTEIN
|
|
US9295673B2
(en)
|
2011-02-23 |
2016-03-29 |
Intellikine Llc |
Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
|
|
EP2683243A4
(en)
*
|
2011-03-09 |
2014-12-03 |
Celgene Avilomics Res Inc |
PI3 KINASE INHIBITORS AND USES THEREOF
|
|
US9834518B2
(en)
|
2011-05-04 |
2017-12-05 |
Ariad Pharmaceuticals, Inc. |
Compounds for inhibiting cell proliferation in EGFR-driven cancers
|
|
WO2012154610A1
(en)
*
|
2011-05-06 |
2012-11-15 |
Intellikine, Llc |
Reactive pi3k kinase inhibitors and uses thereof
|
|
WO2012154608A1
(en)
*
|
2011-05-06 |
2012-11-15 |
Intellikine, Llc |
Reactive mtor and pi3 kinase inhibitors and uses thereof
|
|
US8889716B2
(en)
|
2011-05-10 |
2014-11-18 |
Chdi Foundation, Inc. |
Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
|
|
US9138436B2
(en)
|
2011-07-13 |
2015-09-22 |
Pharmacyclics Llc |
Inhibitors of Bruton's tyrosine kinase
|
|
KR20140069235A
(ko)
|
2011-09-27 |
2014-06-09 |
노파르티스 아게 |
돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
|
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
|
AU2013241854B2
(en)
*
|
2012-03-28 |
2017-11-02 |
Intervet International B.V. |
Heteroaryl compounds with cyclic bridging unit for use in the treatment helminth infection
|
|
EP2836482B1
(en)
|
2012-04-10 |
2019-12-25 |
The Regents of The University of California |
Compositions and methods for treating cancer
|
|
WO2013154778A1
(en)
*
|
2012-04-11 |
2013-10-17 |
Dana-Farber Cancer Institute, Inc. |
Host targeted inhibitors of dengue virus and other viruses
|
|
DK2841075T3
(da)
|
2012-04-26 |
2020-06-22 |
Massachusetts Gen Hospital |
Midler og fremgangsmåder til behandling og forebyggelse af seboroisk keratose
|
|
US20150166591A1
(en)
|
2012-05-05 |
2015-06-18 |
Ariad Pharmaceuticals, Inc. |
Methods and compositions for raf kinase mediated diseases
|
|
US20150204846A1
(en)
*
|
2012-05-15 |
2015-07-23 |
New York University |
Phosphatidylinositol-3-kinase c2 beta modulators and methods of use thereof
|
|
WO2014012093A1
(en)
*
|
2012-07-13 |
2014-01-16 |
Wake Forest University Health Sciences |
Prostate cancer targeted prodrugs and methods of use thereof
|
|
WO2014022569A1
(en)
*
|
2012-08-03 |
2014-02-06 |
Principia Biopharma Inc. |
Treatment of dry eye
|
|
KR102083700B1
(ko)
|
2012-08-21 |
2020-03-02 |
옵코 파마슈티칼스, 엘엘씨 |
리포좀 제제
|
|
US11458199B2
(en)
|
2012-08-21 |
2022-10-04 |
Opko Pharmaceuticals, Llc |
Liposome formulations
|
|
ME03455B
(me)
|
2012-09-10 |
2020-01-20 |
Principia Biopharma Inc |
Jedinjenja pirazolopirimidina kao inhibitori kinaze
|
|
US10000483B2
(en)
|
2012-10-19 |
2018-06-19 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
|
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
|
NZ708864A
(en)
|
2012-12-21 |
2016-09-30 |
Gilead Calistoga Llc |
Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
|
|
JP6207100B2
(ja)
|
2012-12-21 |
2017-10-04 |
ギリアード カリストガ エルエルシー |
イソキノリノンまたはキナゾリノンホスファチジルイノシトール３−キナーゼ阻害剤
|
|
JP2016510000A
(ja)
*
|
2013-02-20 |
2016-04-04 |
カラ ファーマシューティカルズ インコーポレイテッド |
治療用化合物およびその使用
|
|
EP2970240B1
(en)
|
2013-03-14 |
2018-01-10 |
Novartis AG |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
|
|
MX394360B
(es)
|
2013-03-14 |
2025-03-24 |
Sumitomo Pharma Oncology Inc |
Inhibidores de jak2 y alk2 y metodos para su uso.
|
|
JP6473133B2
(ja)
*
|
2013-03-15 |
2019-02-20 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓｇ１２ｃの共有結合性阻害剤
|
|
EP2968340A4
(en)
*
|
2013-03-15 |
2016-08-10 |
Intellikine Llc |
COMBINING KINASE INHIBITORS AND USES THEREOF
|
|
US9745319B2
(en)
|
2013-03-15 |
2017-08-29 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the GTPase K-Ras G12C
|
|
UY35464A
(es)
|
2013-03-15 |
2014-10-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
|
JP6378918B2
(ja)
*
|
2013-04-03 |
2018-08-22 |
株式会社ヤクルト本社 |
チアゾリジン誘導体又はその塩を有効成分とするＰｉｍ阻害剤
|
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
|
PH12019502378A1
(en)
|
2013-05-01 |
2022-05-11 |
Hoffmann La Roche |
Biheteroaryl compounds and uses thereof
|
|
WO2014186663A2
(en)
*
|
2013-05-17 |
2014-11-20 |
The General Hospital Corporation |
Methods for detecting and treating variants of seborrheic keratoses
|
|
ES2667173T3
(es)
|
2013-06-14 |
2018-05-09 |
Gilead Calistoga Llc |
Inhibidores de fosfatidilinositol 3-quinasa
|
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
|
CA2925124A1
(en)
|
2013-09-30 |
2015-04-02 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Ｋｒａｓ ｇ１２ｃ之抑制劑
|
|
JP6223563B2
(ja)
|
2013-10-14 |
2017-11-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
選択的に置換されたキノリン化合物
|
|
CN105636945B
(zh)
|
2013-10-14 |
2017-11-17 |
卫材R&D管理有限公司 |
选择性取代的喹啉化合物
|
|
EP3057955B1
(en)
*
|
2013-10-18 |
2018-04-11 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of prolferative diseases
|
|
CN104447740B
(zh)
|
2013-11-20 |
2017-02-22 |
北京富龙康泰生物技术有限公司 |
咪唑酮类衍生物、其药物组合物和用途
|
|
EP3076968B1
(en)
|
2013-12-02 |
2019-04-17 |
ChemoCentryx, Inc. |
Ccr6 compounds
|
|
PT3107544T
(pt)
|
2014-02-21 |
2021-01-05 |
Principia Biopharma Inc |
Sais e forma sólida de um inibidor de btk
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
ES2826443T3
(es)
*
|
2014-09-25 |
2021-05-18 |
Araxes Pharma Llc |
Inhibidores de proteínas mutantes KRAS G12C
|
|
US10011600B2
(en)
|
2014-09-25 |
2018-07-03 |
Araxes Pharma Llc |
Methods and compositions for inhibition of Ras
|
|
US10485797B2
(en)
|
2014-12-18 |
2019-11-26 |
Principia Biopharma Inc. |
Treatment of pemphigus
|
|
PT3236983T
(pt)
|
2014-12-24 |
2019-07-23 |
Kither Biotech S R L |
Novo péptido inibidor de pi3k gama para tratamento de doenças do sistema respiratório
|
|
JP2018513853A
(ja)
|
2015-04-10 |
2018-05-31 |
アラクセス ファーマ エルエルシー |
置換キナゾリン化合物およびその使用方法
|
|
JP6789239B2
(ja)
|
2015-04-15 |
2020-11-25 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法
|
|
WO2016172952A1
(zh)
|
2015-04-30 |
2016-11-03 |
江苏挪贝肽医药科技有限公司 |
PI4KIIIα蛋白及相关的膜蛋白复合体在治疗阿尔茨海默病中的应用
|
|
HK1245095A1
(zh)
|
2015-05-20 |
2018-08-24 |
Novartis Ag |
依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合
|
|
TW201718572A
(zh)
|
2015-06-24 |
2017-06-01 |
普林斯匹亞生物製藥公司 |
酪胺酸激酶抑制劑
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
US10647703B2
(en)
|
2015-09-28 |
2020-05-12 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
EP3356354A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
US10882847B2
(en)
|
2015-09-28 |
2021-01-05 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356353A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058807A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
JP2018533939A
(ja)
|
2015-10-19 |
2018-11-22 |
アラクセス ファーマ エルエルシー |
Ｒａｓの阻害剤をスクリーニングするための方法
|
|
KR20180081596A
(ko)
|
2015-11-16 |
2018-07-16 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
|
WO2017100546A1
(en)
|
2015-12-09 |
2017-06-15 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
|
RU2617694C1
(ru)
*
|
2015-12-24 |
2017-04-26 |
Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) |
Амиды акриловой и метакриловой кислот с олигопиперидинами и способ их получения
|
|
RU2617409C1
(ru)
*
|
2015-12-24 |
2017-04-25 |
Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) |
Амиды акриловой и метакриловой кислот с n-алкилпиперазино-пиперидинами и способ их получения
|
|
GB201602527D0
(en)
*
|
2016-02-12 |
2016-03-30 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
WO2017172979A1
(en)
|
2016-03-30 |
2017-10-05 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
|
AU2017269335B2
(en)
|
2016-05-26 |
2021-07-01 |
Recurium Ip Holdings, Llc |
EGFR inhibitor compounds
|
|
MA45547A
(fr)
|
2016-06-29 |
2019-05-08 |
Principia Biopharma Inc |
Formulations à libération modifiée à base de 2-[3-[4-amino-3-(2-fluoro-4-phénoxy-phényl)pyrazolo[3,4-d]pyrimidine-1-yl]pipéridine-1-carbonyl]-4-méthyl-4-[4-(oxétane-3-yl)pipérazine-1-yl]pent-2-ènenitrile
|
|
WO2018002958A1
(en)
|
2016-06-30 |
2018-01-04 |
Sun Pharma Advanced Research Company Limited |
Novel hydrazide containing compounds as btk inhibitors
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
TW201813963A
(zh)
|
2016-09-23 |
2018-04-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
|
TW201825465A
(zh)
|
2016-09-23 |
2018-07-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
|
TW201815787A
(zh)
|
2016-09-23 |
2018-05-01 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
|
US10280172B2
(en)
|
2016-09-29 |
2019-05-07 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
EP3523289A1
(en)
|
2016-10-07 |
2019-08-14 |
Araxes Pharma LLC |
Heterocyclic compounds as inhibitors of ras and methods of use thereof
|
|
CN110114070A
(zh)
|
2016-11-23 |
2019-08-09 |
诺华公司 |
使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法
|
|
CN106755343A
(zh)
*
|
2016-12-01 |
2017-05-31 |
北京致成生物医学科技有限公司 |
胰腺癌预后诊断分子标记物
|
|
WO2018140513A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
CN110382482A
(zh)
|
2017-01-26 |
2019-10-25 |
亚瑞克西斯制药公司 |
稠合的杂-杂二环化合物及其使用方法
|
|
WO2018140514A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
US10858351B2
(en)
*
|
2017-04-26 |
2020-12-08 |
Alberta Research Chemicals Inc. |
Substituted tetrahydropyridine derivatives as IDO-1 inhibitors and uses thereof
|
|
JP2020521741A
(ja)
|
2017-05-25 |
2020-07-27 |
アラクセス ファーマ エルエルシー |
がんの処置のための化合物およびその使用の方法
|
|
AU2018271990A1
(en)
|
2017-05-25 |
2019-12-12 |
Araxes Pharma Llc |
Covalent inhibitors of KRAS
|
|
US11639346B2
(en)
|
2017-05-25 |
2023-05-02 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
|
|
US10596165B2
(en)
|
2018-02-12 |
2020-03-24 |
resTORbio, Inc. |
Combination therapies
|
|
CN112533602A
(zh)
|
2018-04-05 |
2021-03-19 |
大日本住友制药肿瘤公司 |
Axl激酶抑制剂及其用途
|
|
ES3032793T3
(en)
|
2018-04-10 |
2025-07-24 |
Neuropore Therapies Inc |
Tri-substituted aryl and heteroaryl derivatives as modulators of pi3-kinase and autophagy pathways
|
|
CN112533917B
(zh)
|
2018-04-10 |
2024-06-21 |
神经孔疗法股份有限公司 |
作为vps34的抑制剂的吗啉衍生物
|
|
MX2021000977A
(es)
|
2018-07-26 |
2021-04-12 |
Sumitomo Pharma Oncology Inc |
Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.
|
|
MX2021000887A
(es)
*
|
2018-08-01 |
2021-03-31 |
Araxes Pharma Llc |
Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
|
|
KR102328682B1
(ko)
|
2018-08-27 |
2021-11-18 |
주식회사 대웅제약 |
신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
|
|
WO2020053125A1
(en)
*
|
2018-09-10 |
2020-03-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of neurofibromatosis
|
|
EP3898615A1
(en)
|
2018-12-19 |
2021-10-27 |
Array Biopharma, Inc. |
7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
|
|
WO2020131627A1
(en)
|
2018-12-19 |
2020-06-25 |
Array Biopharma Inc. |
Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
|
|
KR20220079866A
(ko)
*
|
2019-09-19 |
2022-06-14 |
토투스 메디신스 아이엔씨. |
치료 접합체
|
|
TWI877239B
(zh)
|
2019-10-14 |
2025-03-21 |
美商普林斯匹亞生物製藥公司 |
藉由投予(R)-2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧呾-3-基)哌-1-基]戊-2-烯腈來治療免疫血小板減少症之方法
|
|
EP4045908A1
(en)
|
2019-10-18 |
2022-08-24 |
The Regents Of The University Of California |
Ex vivo tumor angiogenesis model
|
|
EP4045485A1
(en)
|
2019-10-18 |
2022-08-24 |
The Regents Of The University Of California |
3-phenylsulphonyl-quinoline derivatives as agents for treating pathogenic blood vessels disorders
|
|
US20210269434A1
(en)
*
|
2020-01-10 |
2021-09-02 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
|
WO2021150613A1
(en)
|
2020-01-20 |
2021-07-29 |
Incyte Corporation |
Spiro compounds as inhibitors of kras
|
|
JP2023511105A
(ja)
|
2020-01-22 |
2023-03-16 |
プリンシピア バイオファーマ インコーポレイテッド |
２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）－１ｈ－ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルの結晶形態
|
|
AU2021224588B2
(en)
|
2020-02-18 |
2024-07-18 |
Gilead Sciences, Inc. |
Antiviral compounds
|
|
TWI794742B
(zh)
|
2020-02-18 |
2023-03-01 |
美商基利科學股份有限公司 |
抗病毒化合物
|
|
TWI775313B
(zh)
|
2020-02-18 |
2022-08-21 |
美商基利科學股份有限公司 |
抗病毒化合物
|
|
US11739102B2
(en)
|
2020-05-13 |
2023-08-29 |
Incyte Corporation |
Fused pyrimidine compounds as KRAS inhibitors
|
|
WO2021242859A1
(en)
*
|
2020-05-27 |
2021-12-02 |
Duke University |
Compositions and methods for sensitizing acute myeloid leukemias to chemotherapy
|
|
US11999752B2
(en)
|
2020-08-28 |
2024-06-04 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of KRAS
|
|
WO2022072783A1
(en)
|
2020-10-02 |
2022-04-07 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of kras
|
|
CN113045582B
(zh)
*
|
2021-02-05 |
2022-12-23 |
中国药科大学 |
Parp-1/pi3k双靶点抑制剂或其药学上可接受的盐及其制备方法与用途
|
|
WO2022198024A1
(en)
*
|
2021-03-18 |
2022-09-22 |
Totus Medicines Inc. |
Therapeutic conjugates
|
|
WO2022204112A1
(en)
|
2021-03-22 |
2022-09-29 |
Incyte Corporation |
Imidazole and triazole kras inhibitors
|
|
CN117396470A
(zh)
*
|
2021-04-09 |
2024-01-12 |
巴塞尔大学 |
作为pi3k的可逆和不可逆共价抑制剂的三嗪衍生物
|
|
EP4320115A1
(en)
*
|
2021-04-09 |
2024-02-14 |
Universität Basel |
Triazine derivative as reversible and irreversible covalent inhibitors of pi3k
|
|
EP4323362B1
(en)
|
2021-04-16 |
2025-05-07 |
Gilead Sciences, Inc. |
Methods of preparing carbanucleosides using amides
|
|
MX2024000357A
(es)
|
2021-07-07 |
2024-02-12 |
Incyte Corp |
Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras).
|
|
US12600717B2
(en)
|
2021-07-14 |
2026-04-14 |
Incyte Corporation |
Tricyclic compounds as inhibitors of KRAS
|
|
WO2023009785A1
(en)
*
|
2021-07-29 |
2023-02-02 |
Cedilla Therapeutics, Inc. |
Tead inhibitors and uses thereof
|
|
AU2022328698B2
(en)
|
2021-08-18 |
2025-02-20 |
Gilead Sciences, Inc. |
Phospholipid compounds and methods of making and using the same
|
|
US12441742B2
(en)
|
2021-08-31 |
2025-10-14 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of KRAS
|
|
WO2023049697A1
(en)
|
2021-09-21 |
2023-03-30 |
Incyte Corporation |
Hetero-tricyclic compounds as inhibitors of kras
|
|
CN113754680B
(zh)
*
|
2021-09-28 |
2022-07-22 |
云白药征武科技(上海)有限公司 |
一种α氟代酰基哌嗪衍生物及其制备和应用
|
|
CA3234375A1
(en)
|
2021-10-01 |
2023-04-06 |
Incyte Corporation |
Pyrazoloquinoline kras inhibitors
|
|
WO2023064857A1
(en)
|
2021-10-14 |
2023-04-20 |
Incyte Corporation |
Quinoline compounds as inhibitors of kras
|
|
KR102939621B1
(ko)
*
|
2022-07-21 |
2026-03-17 |
주식회사 바오밥에이바이오 |
헤테로비시클릭 화합물 및 그를 포함하는 약제학적 조성물
|
|
WO2024182447A1
(en)
*
|
2023-02-28 |
2024-09-06 |
Vividion Therapeutics, Inc. |
Compounds and methods for modulating ras-pi3k
|
|
WO2025188658A1
(en)
*
|
2024-03-06 |
2025-09-12 |
Alterome Therapeutics, Inc. |
Akt1 modulators
|